Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Left Ventricular Dysfunction During Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients 18-70 years old~* Sinus rhythm~* Normal LVEF (\>=50%)~* Patients recently diagnosed of acute leukemia to be submitted to intensive chemotherapy or~* Patients with other hemopathies submitted to autologous peripheral blood stem cell transplantation~* Signed informed consent~Exclusion Criteria:~* Congestive heart failure~* LVEF\<50%~* Coronary artery disease,~* significant valvulopathy or myocardiopathy~* Renal failure (MDRD\<30)~* Liver failure~* Ongoing or expected need to be treated with angiotensin-converting enzyme inhibitors (ACE-i),angiotensin II receptor blockers (ARB) or beta-blockers~* Prior allergy to ACEI or ARB~* Systolic blood pressure \<90 mmHg~* Asthma~* Auriculoventricular (AV) block or sinus bradycardia (HR\<60 bpm)~* Persistent atrial fibrillation~* Need to be treated with Class I antiarrhythmic drugs~* Pregnancy~* Inability or unwillingness to give unformed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Enalapril and carvedilol (Type: EXPERIMENTAL): Enalapril 2.5 to 10 mg BID plus Carvedilol 6.25 to 25 mg BID
- Control (Type: NO_INTERVENTION): Control arm without intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).